Sirakov Stanimir S, Sirakov Alexander, Minkin Krasimir, Hristov Hristo, Ninov Kristian, Penkov Marin, Karakostov Vasil, Orlov Kirill, Gorbatykh Anton, Kislitsin Dmitry, Raychev Radoslav
1 Radiology Department, UH St Ivan Rilski, Sofia, Bulgaria.
2 Neurosurgery Department, UH St Ivan Rilski, Sofia, Bulgaria.
Interv Neuroradiol. 2019 Feb;25(1):58-65. doi: 10.1177/1591019918798808. Epub 2018 Sep 17.
Precipitating hydrophobic injectable liquid is a newly introduced liquid embolic agent for endovascular embolization with some technical advantages over other liquid embolic agents. We present our initial experience with precipitating hydrophobic injectable liquid in the endovascular treatment of cerebral arteriovenous malformations.
From October 2015 to January 2018, 27 patients harboring cerebral arteriovenous malformations underwent endovascular embolization with precipitating hydrophobic injectable liquid 25. Clinical features, angiographic results, procedural details, complications, and follow-up details were retrospectively analyzed.
Twenty-seven patients with cerebral arteriovenous malformations were included. Total obliteration in one endovascular session was confirmed for 14/27 (52%) patients. Partial embolization was attained in 13 patients (48%) in whom staged treatment with following radiosurgery or surgery was planned. No mortality was recorded in this series. Complications during or after the embolization occurred in six of 27 (22.2%) patients.
In our initial experience, precipitating hydrophobic injectable liquid has acceptable clinical outcome comparable to other liquid embolic agents. Although this is the largest reported study in arteriovenous malformation treatment with precipitating hydrophobic injectable liquid, further studies are needed to validate its safety and efficacy.
沉淀型疏水性可注射液体是一种新引入的用于血管内栓塞的液体栓塞剂，与其他液体栓塞剂相比具有一些技术优势。我们介绍了使用沉淀型疏水性可注射液体进行脑动静脉畸形血管内治疗的初步经验。
2015年10月至2018年1月，27例患有脑动静脉畸形的患者接受了25次沉淀型疏水性可注射液体血管内栓塞治疗。对临床特征、血管造影结果、手术细节、并发症及随访细节进行回顾性分析。
纳入27例脑动静脉畸形患者。27例患者中有14例（52%）在一次血管内治疗中实现了完全闭塞。13例患者（48%）实现了部分栓塞，计划对其进行后续的放射外科或手术分期治疗。本系列未记录到死亡病例。27例患者中有6例（22.2%）在栓塞期间或之后出现并发症。
根据我们的初步经验，沉淀型疏水性可注射液体具有与其他液体栓塞剂相当的可接受的临床效果。尽管这是关于使用沉淀型疏水性可注射液体治疗动静脉畸形的最大规模报道研究，但仍需要进一步研究以验证其安全性和有效性。
